Skip to main content

Innovations To Take The CAR T-Cell Therapy Market At A Greater Stride

The CAR T-Cell Therapy Market is all set to create greater strides in the upcoming period. Big data analytics is flowing through the veins of the healthcare vertical these days. This practice helps in providing better insights to healthcare practitioners. The healthcare vertical has started depending on analytics’ expertise for deciphering data collected through various sources and monitoring processes’ efficiency.

According to a recent study by Persistence Market Research, the global CAR T-cell therapy market is anticipated to experience high growth over the coming years. The market is expected to grow from US$ 1.2 Bn in 2020 to over US$ 2.8 Bn by 2031, which reflects a CAGR of around 5.6% for the next ten years.

Key players in the CAR T-cell therapy space are focusing on acquisitions and collaborations with other players of the market to strengthen their position by offering a wide range of products.

  • For instance, in December 2017, Gilead Science acquired Cell Design Labs Inc., which is a privately held company of biotherapeutics that discovers and develops cell-based therapies. This acquisition benefits Gilead through gaining novel technology platforms that will its boost R&D efforts in cellular therapy.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/28264

Also, increasing number of clinical trials in the field of life sciences and CAR T-cells will benefit manufacturers and researchers in developing innovative cancer therapy. With a large extent of studies taking place around CAR T-cell therapy, it is anticipated to enhance product availability in the market over the coming years.

  • For instance, the experiment on AntiCD19 Chimeric Antigen Receptor T Cells for the treatment of relapsed or refractory Non-Hodgkin lymphoma by Benjamin Tomlinson is undergoing and is currently in phase I clinical trial.
  • Another study by Janssen Research & Development, LLC of a chimeric antigen receptor T Cell (CAR-T) therapy for myeloma is in phase 2 clinical trial.
  • Furthermore, a study on the safety and efficacy of ALLO-605 in patients with relapsed/refractory multiple myeloma by Allogene Therapeutics is currently in phase 2.

All these factors will drive demand for CAR T-cell therapy during the forecast period (2021 to 2031).

Company Profiles:

  • Novartis AG
  • Gilead Sciences Inc.
  • Celgene Corporation
  • bluebird bio, Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/28264

car-t-cell-therapy-market

Key Takeaways from Market Study

  • By product, Yescarta (axicabtagene ciloleucel) holds high share of approximately 59%.
  • By indication, relapsed large B-cell lymphoma accounts for approximately 93% market share.
  • By end user, cancer treatment centers account for around 92% share in the market.
  • By region, North America holds the largest share of 68.1% of the global CAR T-cell therapy market, due to increasing number of life science companies focusing on the development and commercial manufacturing of CAR T-cells in the region.

“Increasing prevalence of cancer and continuous R&D on cell-based therapies are expected to drive demand for CAR T-cell therapy over the decade,” says a Persistence Market Research analyst.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/28264

Who is Winning in This Space?

Many of the chief players in the CAR T-cell therapy market are focusing on product launches and collaborations for global expansion.

  • In March 2018, Celgene Corporation completed the acquisition of Juno Therapeutics, Inc. This acquisition helps Celgene advance in cellular immunotherapy by adding novel technology and advanced cellular manufacturing capabilities to its portfolio.
  • In August 2017, Gilead Science announced the acquisition of Kite Pharma Inc., an industry leader in the emerging field of cell therapy.
  • In March 2021, Kite Pharma gained FDA approval for axicabtagene ciloleucel (axi-cel), a CAR T-cell based therapy.

Want More Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031.

The market is segmented in detail based on product (Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel), JCAR017 (lisocabtagene maraleucel), and bb2121) indication (Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma), and end user (hospitals and cancer treatment centers), across seven major regions of the world.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Top Market Insights

The Insulin Delivery Device Market To Show Constructive Disruption With US$ 14.09 Billion

Persistence Market Research Released New Market Report on “Global Market Study on Insulin Delivery Devices - Asia to Witness Highest Growth by 2020” the global insulin delivery devices market is estimated at USD 9,391.1 million in 2014 and is expected to grow at a  CAGR of 7%  from 2014 to 2020, to reach an estimated value of  USD 14,093.3 million in 2020 . The insulin delivery devices market is witnessing a significant growth due to the increasing prevalence of diabetes and rising obese endemic. In addition, advanced features of insulin delivery devices and rising awareness among people about diabetes care are also supporting in the growth of the global insulin delivery devices market. Get Going With Sample Of Insulin Delivery Device Market Report!  https://www.persistencemarketresearch.co/samples/2823 Some of the major players operating in the market: Abbott Laboratories. Novo Nordisk A/S. Eli Lilly and Company. Medtronic, Inc. Sanofi, Becton. Dickinson and Company...

The Bioinformatics Market To Grow Inadvertently

The Bioinformatics Market is bound to grow vigorously in the next 10 years. IoT has already made a beeline to the healthcare vertical. This has, in turn, enabled tracking of real-time locations of the apparatus and medical devices like scales, wheelchairs, defibrillators, or nebulizers along with remote monitoring. The entire healthcare vertical is expected to run on the IoT wave going forward.   The global  bioinformatics market  is exhibiting a  20.40% CAGR  from 2014 to 2020, according to a new market study recently released by Persistence Market Research. The market was calculated to be worth  US$4.1 bn  in 2014 and is estimated to reach  US$12.5 bn  by 2020, says PMR’s report, titled ‘ Global Market Study on Bioinformatics – Asia to Witness Fastest Growth by 2020 ’.   Get Going With Sample Of Bioinformatics Market Report!  https://www.persistencemarketresearch.com/samples/2778   The bioinformatics market is drive...

The Next 10 Years To Witness Formidable Growth Of Hospital Acquired Pneumonia Prevention Market (CAGR Of 4.7%) Between 2026

  The   Hospital Acquired Pneumonia Prevention Market Share   is estimated to be reaching   US$ 1,100 Million   at a   CAGR of 4.7%   from   2026 . With advanced digitization driving the healthcare industry, the concept of a “global village” has become a reality. As such, medical treatment could be sought to transcend the geographical barriers, which would form the focal point of the healthcare industry going forward. Over an eight-year period of assessment 2018-2026, the global market for hospital-acquired pneumonia prevention is poised to witness moderate growth, according to a recent research report on the global  hospital-acquired pneumonia prevention market . The report has been published by Persistence Market Research and is titled, “Hospital-Acquired Pneumonia Prevention Market: Global Industry Analysis 2013 – 2017 and Forecast 2018 – 2026.” The  US$ 795 Mn  market is likely to exhibit a CAGR of 4.7%, reaching a value in exce...

The Next Decade To Sparkle With Acne Treatment Market Growing At The Rate Of 4.6% From 2025

  The   Acne Treatment Market Share   is estimated to be reaching   US$ 4,500 Million   at a   CAGR of 4.6%   from   2025 . With advanced digitization driving the healthcare industry, the concept of a “global village” has become a reality. As such, medical treatment could be sought to transcend the geographical barriers, which would form the focal point of the healthcare industry going forward. The average age of onset of acne has reduced from 14-15 years to 11-12 years due to changing demographics and social habits. Moreover, some of the misleading media content continue to encourage the habit of self-medication that often backfires, resulting in further complication. Over the past couple of years, demand for acne treatment drugs and medications has surged at a remarkable pace. After conducting an exclusive study, Persistence Market Research (PMR) identified that approximately 20% of the young population (aged below 13 years) suffer from moderate...

Opioids Market to Register CAGR 4.7% Increase in Revenue by 2021 End

  Persistence Market Research (PMR) delivers key insights on the Global   Opioids Market   in its latest report titled “Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period ”.The global opioids market is anticipated to exhibit a stable CAGR during the forecast period (2015-2021). By product type, the global opioids market is segmented into morphine, codeine, fentanyl, meperidine and methadone. Morphine segment was the largest contributor in overall opioids market, accounting for around 36% share in 2014. However, fentanyl segment is expected to register fastest CAGR of 4.7% during the forecast period. Synthetic opioids such as fentanyl, meperidine and methadone have lucrative growth opportunities in opioids market, owing to their potential application in opioid substitution treatment and fewer side effects as compared to natural opioids. Get Sample Copy of Report @  https://www.persis...

Geographical Expansion To Catalyze The HPMC Capsules Market (US$ 120 Million) From 2025

  The   Global HPMC Capsules Market Share  is expected to reach   US$ 120 Million   at a CAGR of   10.9%   between   2025 . With “brand building” taking the center stage, the healthcare vertical would also be vying for brand building. In other words, increased visibility online would help the healthcare marketing service providers in making greater strides with regards to patient experience, right from drugs to treatment. HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in several parts of the world. Moreover, these capsules can significantly boost the body metabolism by improving absorption and digestion of protein, fat and carbohydrates. HPMC capsules find their application in the preparation of non-animal based medicines and cosmetics & nutraceuticals products. Persistence Market Research (PMR) recently conducted a study on the  global HPMC capsules market ...

The Peripheral Intravenous Catheter Market Is Expected To Grow On An Irrevocable Not At The Rate Of 7% Between 2019 to 2029

The  Global Peripheral Intravenous Catheter Market Share  is expected to reach  US$ 4.9 Billion  at a CAGR of  7%  between  2019 to 2029 . With “brand building” taking the center stage, the healthcare vertical would also be vying for brand building. In other words, increased visibility online would help the healthcare marketing service providers in making greater strides with regards to patient experience, right from drugs to treatment. Increasing hospitalizations, anticipated rise in cancer incidence, and higher demand for infused chemotherapy agents are fuelling the need for higher quality catheters for safe usage. Furthermore, rising number of biologic approvals is increasing the demand for infusion therapies. The global peripheral intravenous catheters market was valued at  US$ 4.9 Bn  in  2020 , and is expected to witness a healthy  CAGR of 7%  during the forecast period ( 2020 – 2030 ). Strategizi...

The Perfusion Bioreactors Market Is Expected To Grow On An Irrevocable Not At The Rate Of 7.5% Between 2021-2031

  The   Ischemic Optic Neuropathy Treatment Market Share  is expected to reach   US$ 187.7 Mn   at the rate of   3.7%   from   2021-2031 . With effective remote monitoring, the healthcare vertical is onto the awareness-building spree, so that patients could get benefited out of these services, telehealth, in particular. As such, several informative landing pages could be seen about the remote monitoring software. Ischemic optic neuropathy occurs because of a small vessel infraction of the optic nerve, and is a significant reason for impaired vision or blindness. Increasing utilization of newly approved intravitreal implants for the treatment of optic nerve disorders is expected to drive the market over the coming years. With developing awareness toward eye-associated inconveniences that give rise to impaired vision, diabetic patients and the geriatric population in developed nations are believed to have a proactive methodology for treatment-associ...

Sequential Advancements In Technology To Drive The Autogenous Vaccine For Aquaculture Market

  The   Autogenous Vaccine For Aquaculture Market Share  is expected to reach   US$ 11 Mn   between   2020 to 2030   at a   CAGR of 6% . Speedy development on the part of ICT does bring in new-fangled advantages like more autonomy to patients along with the promotion of interagency collaboration. As such, the ones with comorbidities and multidimensional problems would find themselves safe. This increased dependency is bound to drive the healthcare vertical going forward. Fish is a widely consumed food across the world. In 2019, 177.8 million metric tons of fish were produced globally. In spite of such huge production in aquaculture, bacterial disease is a major issue, and is causing multibillion-dollar losses annually. In developing countries, fish diseases often spread quickly between small-scale aquaculture farms. Rising prevalence of infectious diseases such as bacterial diseases, viral diseases, and parasitic and fungal diseases amongst fish s...

Medical Tapes Market to Generate Lucrative Revenue Prospects for Manufacturers

  In a new report titled  ‘Medical Tapes Market: Global Industry Analysis and Forecast 2016 – 2024’,  Persistence Market Research analyzes the performance of the global  medical tapes market  over an eight-year period and provides insights on the key factors and trends likely to influence the market during the forecast period (2016 – 2024). The global medical tapes market is expected to register a  CAGR of 5.8%  during the forecast period 2016–2024. In this report, the global medical tapes market is tracked in terms of value and is calibrated to obtain market revenue estimates. Get Sample Copy of Report @  https://www.persistencemarketresearch.com/samples/3435 Company Profile 3M Johnson & Johnson Paul Hartmann AG. Scapa Group PLC Andover Healthcare Inc. Ad Tape & Label Medtronic Get To Know Methodology of Report @  https://www.persistencemarketresearch.com/methodology/3435 Market dynamics Rising incidences of Healthcare Acquired Infec...